Immunomax specializes in immunology-based biopharmaceuticals, developing allogeneic gamma delta CAR-T cell therapies and high-efficiency biopharmaceutical production animal cell lines.

Vision and Mission: To contribute to human health by pioneering in the field of immunology, offering innovative treatments and advancing medical science.

Noteworthy Points:

• Founded in 2015 and operating actively.
• Last funding round was a Venture – Series Unknown.
• Competitors include DongKwang Pharm, AL Biotech, and ENCell.